Despite an unusual lack of major announcements, energy is high. And a few key themes dominate discussions.
Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback